Responses of state medicaid programs to buprenorphine diversion: Doing more harm than good?

JAMA Internal Medicine

Volumn 173, Issue 17, 2013, Pages 1571-1572

  Clark, Robin E ^a   Baxter, Jeffrey D ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE;

DRUG MISUSE; DRUG PROGRAM; HUMAN; MEDICAID; OPIATE ADDICTION; PRESCRIPTION; PRIORITY JOURNAL; SHORT SURVEY;

BUPRENORPHINE; HUMANS; MEDICAID; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; UNITED STATES;

EID: 84884688253     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2013.9059     Document Type: Short Survey

References (10)

1. CDC Grand Rounds: prescription drug overdoses: a US epidemic. Morb Mortal Wkly Rep. 2012;61(01):10-13. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6101a3. htm?s-cid=mm6101a3-w. Accessed June 26, 2013.
2. The DAWN Report: Emergency Department Visits Involving Buprenorphine. Rockville, MD: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality; 2013.
3. Adelmann PK. Mental and substance use disorders among Medicaid recipients: prevalence estimates from two national surveys. Adm Policy Ment Health. 2003;31(2):111-129. (Pubitemid 37553467)
4. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008;16(2):CD002207.
5. Kim HK, Smiddy M, Hoffman RS, Nelson LS. Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure. Pediatrics. 2012;130(6):e1700-e1703.
6. Clark RE, Samnaliev M, Baxter JD, Leung GY. The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff (Millwood). 2011;30(8):1425-1433.
7. Bronstein AC, Spyker DA, Cantilena LR Jr, Rumack BH, Dart RC. 2011 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th Annual Report. Clin Toxicol (Phila). 2012;50(10):911-1164.
8. Lofwall MR, Havens JR. Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine. Drug Alcohol Depend. 2012;126(3):379-383.
9. Johanson CE, Arfken CL, di Menza S, Schuster CR. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians. Drug Alcohol Depend. 2012;120(1-3):190-195.
10. American Society of Addiction Medicine. Public policy statement on pharmacological therapies of opioid use disorder. http://www.asam.org/advocacy/ find-a-policy-statement/view-policy-statement/public-policy-statements/2013/04/ 25/pharmalogical-therapies-for-opioid-use-disorders. Accessed May 17, 2013.